---
schema_version: "secwatch.filing_event.v1"
accession: "0001725160-24-000057"
form_type: "8-K"
ticker: "ZNTL"
cik: "0001725160"
company_name: "Zentalis Pharmaceuticals, Inc."
filed_at: "2024-02-15T23:59:59+00:00"
generated_at: "2026-06-06T01:20:26.451100+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.15
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# Zentalis adopts amended bylaws with universal proxy rule compliance

## Summary
- Board approved Amended and Restated Bylaws effective February 12, 2024.
- Amendments address SEC universal proxy rules under Rule 14a-19, including notice and solicitation requirements.
- Enhanced disclosure requirements for stockholder director nominations and other business proposals.
- Prohibits proposing more nominees than directors up for election.
- Includes technical, modernizing, clarifying, and conforming changes.

## SEC filing metadata
- accession: 0001725160-24-000057
- form_type: 8-K
- ticker: ZNTL
- cik: 0001725160
- company_name: Zentalis Pharmaceuticals, Inc.
- filed_at: 2024-02-15T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.15
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/0001725160-24-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/zntl-20240212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001725160-24-000057
- JSON: https://secwatch.observer/filing/0001725160-24-000057.json
- Plain text: https://secwatch.observer/filing/0001725160-24-000057.txt

## Key facts
- Governance Changes
  Zentalis Pharmaceuticals, Inc.: Amended and Restated Bylaws to address universal proxy rules, streamline stockholder nomination procedures, and prohibit excessive director nominees; effective February 12, 2024 (effective 2024-02-12).
  - Change: bylaw amendment
  - Effective: 2024-02-12
  source text: On February 12, 2024, the Board of Directors (the “Board”) of Zentalis Pharmaceuticals, Inc., a Delaware corporation (the “Company”) approved and adopted amendments to the Company’s Bylaws (as amended, the “Amended and Restated Bylaws”), which became effective the same day.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1725160/000172516024000057/0001725160-24-000057-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.